Drug intelligence / Profile preview

BEM-041

Development stage: Preclinical
Lead developer: Shanghai Benemae Pharmaceutical
Modality: Peptides
Administration: Subcutaneous

Overview

**BEM-041** is a preclinical antidiabetic combination product from Shanghai Benemae Pharma that combines beinaglutide, a glucagon-like peptide 1 receptor agonist, with mealtime insulin. The program is intended to improve glycemic control in type 2 diabetes by integrating incretin-mediated glucose-dependent insulinotropic activity with prandial insulin replacement. ([benemae.com](https://www.benemae.com/product/research.html))

Other names: 贝那鲁肽 + 餐时胰岛素

Targets

GLP1R (GLP-1R)INSR (Insulin receptor)

Beyond the preview

Go deeper on BEM-041.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEM-041.

Explore the full profile